Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 1029-1036

  Newell, M ^a   Goldstein, D ^b   Milliken, S ^c   Lewis, C ^d   Hoy, J ^b   Thomson, B ^e   Cooper, D ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b FAIRFIELD HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d Prnc Wales Hosp Prnc Wales M   (Australia)

^e Amgen Australia Pty Ltd   (Australia)

Author keywords

AIDS; antineoplastic agents; antiretroviral therapy; G CSF; non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DIDANOSINE; EPIRUBICIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030464820     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010495     Document Type: Article

References (35)

1. Ziegler JL, Miner RC, Rosenbaum E et al. Outbreak of Burkitt's like lymphoma in homosexual men. Lancet 1982; 2: 631-3.
2. Centres for Disease Control. Diffuse undifferentiated non-Hodgkin's lymphoma among homosexual males - United States. MMWR 1982; 31: 277-85.
3. Centres for Disease Control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States. MMWR 1985; 34: 373-5.
4. Australian HIV Surveillance Report 1996; 12 (2).
5. Beral V, Peterman T, Berkelman R et al. AIDS associated non-Hodgkin's lymphoma. Lancet 1991; 337: 805-9.
6. Kaplan L, Northfelt D. Malignancies associated with AIDS. In Sande M, Volberding P (eds): Medical Management of AIDS (ed 4). Philadelphia: Saunders 1995; 555-90.
7. Levine A, Epidemiology, clinical characteristics and management of AIDS-related lymphoma. Haematology/Oncology Clinics of North America 1991; 5(2): 331-43.
8. Kaplan LD, Abrams DI, Feigal D et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261: 719-24.
9. Boyle MJ, Swanson C, Turner J et al. Definition of two distinct types of AIDS-associated non-Hodgkin's lymphoma. Br J Haematol 1990; 76: 506-12.
10. Davis B, Zauli G. Effect of human immunodeficiency virus on haemopoiesis. Bailliere's Clin Haematol 1995; 8(1): 113-30.
11. Lieschke GJ, Burgess AW. Granulocyte colony stimulating factor and granulocyte-macrophage colony-stimulating factor (1 and 2). N Engl J Med 1992; 327: 28-35, 99-106.
12. Groopman JE. Management of the haematologic complications of human immunodeficiency virus infection. Rev Infect Dis 1990; 12: 931-7.
13. Pluda JM, Yarchoan R, Smith PD et al. Subcutaneous recombinant GM-CSF used as a single agent an in an alternating regimen with azidothymidine (AZT) in leukopenic patients with severe human immunodeficiency virus infection. Blood 1990; 76: 463-72.
14. Kaplan LD, Khan JO, Crowe S et al. Clinical and virologic effects on recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for HIV-associated non-Hodgkin's lymphoma: Results of a randomised trial. J Clin Oncol 1991; 9: 929-40.
15. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70.
16. Pettengell R, Gurney H, Radford JA et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomised controlled trial. Blood 1992; 80: 1430-6.
17. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-24.
18. Koyanagi Y, O'Brien WA, Zhao J et al. Cytokines alter production of HIV-I from primary mononuclear phagocytes. Science 1988; 241: 1673.
19. Goldstein D, Milliken S, Cooper DA et al. Modified CEOP in HIV related non-Hodgkin's lymphoma. Proc Int Conf AIDS, Berlin 1993 (Abstr PoB 3109).
20. Gurney H, Dodwell D, Thatcher N et al. Escalating drug delivery in cancer chemotherapy: A review of concepts and practice, Part I. Ann Oncol 1993; 4: 23-4.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
22. Levine A, Wernz JC, Kaplan L et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-rclated lymphoma. JAMA 1991; 266(1): 84-8.
23. Tirelli U, Errante D, Oksenhendler E et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin's lymphoma. Ann Oncol 1992; 3(10): 843-7.
24. Walsh C. Wernz J, Levine A et al. Phase I trial of m-BACOD and granulocyte macrophage colony-stimulating factor in HIV-associated non-Hodgkin's lymphoma. J AIDS 1993; 6(3): 265-70.
25. Tirelli U, Vaccher E. Economic and clinical evaluation of therapy of HIV related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF). Eur J Cancer 1994; 30A(10): 1590-1 (Letter).
26. Kaplan L, Straus D, Teata M et al. Randomised trial of standard dose M-BACOD with GM-CSF vs. reduced dose mBACOD for systemic HIV-associated lymphoma: ACTG 142. Proc ASCO. 1005 (Abstr 818).
27. Hahn S, Pluda J, Shay L et al. Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy, AZT and GM-CSF. Proc Am Soc Clin Oncol 1992; 11 (Abstr 6).
28. Gabarre J, Lerpage E, Thyss A et al. Chemotherapy associated with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma (HIV-NHL). Proc Am Assoc Cancer Res 1994; 35 (Abstr 1138).
29. Bregni M, Siena S, Di Nicola M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-simulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 1996; 14(2): 628-35.
30. Mamounas EP, Anderson S, Wickerham DL et al. The efficacy of rccombinant human granulocyte colony-stimulating factor and granulocyte-macrophage colony-simulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. Am J Clin Oncol 1994; 17(5): 374-81.
31. Al-Ismail SA, Whittaker JA, Gough J. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 1987; 23(9): 1374-84.
32. De Lena M, Maiello E, Lorusso V et al. Comparison of CHOP-B vs. CEOP-B in 'poor prognosis' non-Hodgkins lymphomas - a randomised trial. Med Oncol Tumour Pharmacother 1989; 6(2): 163-9.
33. Deliliers L, Butti C, Baldini L et al. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Haematologica 1995; 80(4): 318-24.
34. Fisher R, Gaynor E, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 29: 1002-6.
35. Harris J, Sengar D, Stewart T et al. The effect of immunosup-pressive chemotherapy on immune function in patients with malignant disease (Review). Cancer 1976; 37: 1058-69.